Longeveron (LGVN) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Longeveron (LGVN) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.21% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 151.28% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 327.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -147.59% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 95.87% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -12.04% |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -22.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.12% |
| Mar 31, 2026 | 14.64% |
| Dec 31, 2025 | -33.40% |
| Sep 30, 2025 | -58.08% |
| Jun 30, 2025 | 57.80% |
| Mar 31, 2025 | -50.58% |
| Dec 31, 2024 | 32.30% |
| Sep 30, 2024 | 22.63% |
| Jun 30, 2024 | -111.54% |
| Mar 31, 2024 | 89.90% |
| Dec 31, 2023 | -35.25% |
| Sep 30, 2023 | -12.59% |
| Jun 30, 2023 | -14.40% |
| Mar 31, 2023 | -942.87% |
| Dec 31, 2022 | -109.93% |
| Sep 30, 2022 | 77.11% |
| Jun 30, 2022 | 75.46% |
| Mar 31, 2022 | 78.95% |
| Dec 31, 2021 | 3,259.89% |
| Sep 30, 2021 | -2,258.91% |